

TABLE OF CONTENTS

	PAGE
ACKNOWLEDGEMENTS	iii
ABSTRACT (in English)	vi
ABSTRACT (in Thai)	viii
ABSTRACT (in French)	x
LIST OF TABLES	xvi
LIST OF FIGURES	xvii
ABBREVIATIONS	xx
CHAPTER 1 : INTRODUCTION	1
1. INTRODUCTION	2
2. BACKGROUND	3
PART I. Human immunodeficiency virus (HIV)	3
1. History of AIDS and HIV discovery	3
2. Current situation of HIV and AIDS epidemic	4
3. HIV structure, genomic organization and replication cycle	6
3.1 Viral structure	6
3.2 Genomic organization	7
3.3 Replication cycle	9
4. HIV envelope glycoproteins	15

4.1 Envelope glycoprotein synthesis and glycosylation	16
4.2 Gp120 structure	16
4.3 Gp41 structure	23
5. HIV coreceptor usage and tropism	25
5.1 HIV coreceptor usage	25
5.2 Definition of HIV tropism	26
PART II. Genetic variability of HIV	29
1. Classification of HIV	29
1.1 HIV types	29
1.2 HIV type 1	29
1.3 HIV type 2	35
2. Global distribution of HIV-1 strains	35
3. Mechanisms of genetic diversity	36
3.1 High mutation rate of reverse transcriptase	36
3.2 High replication rate of HIV	37
3.3 Recombination	37
4. Implications of HIV variability	44
4.1 Transmission and disease progression	44
4.2 Diagnostics	45
4.3 Antiretroviral therapy	46
PART III. Neutralizing antibody against HIV infection	48
1. Antibody responses to HIV infection	48
2. Mechanisms of antibody-mediated protection	49
3. HIV-1 neutralizing monoclonal antibodies	53
4. Primate challenge models and passive immunization	54
5. Viral strategies to avoid neutralizing antibodies	55
PART IV. Mother-to-child transmission of HIV	57
1. Current situation	57

2. Timing and mechanisms	58
2.1 <i>In utero</i> transmission	58
2.1.1 Morphology of the human placenta	58
2.1.2 Mechanism of HIV <i>in utero</i> transmission	61
2.2 Intrapartum transmission	63
2.3 Postpartum transmission	64
3. Risk factors	66
3.1 Maternal factors	66
3.2 Obstetrical factors	68
3.3 Neonatal factors	68
4. Prevention of mother-to-child transmission of HIV	68
4.1 Antiretroviral therapy	68
4.2 Mode of delivery	69
4.3 Breastfeeding interventions	70
4.4 Others interventions	71
CHAPTER 2 : STUDY WORKS	72
1. INTRODUCTION	72
2. OBJECTIVES OF THE ENTIRE STUDY	73
3. MATERIALS AND METHODS, RESULTS, DISCUSSION	74
I. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission in Thailand	74
1. Background and specific aims	74
2. Materials and methods	75
3. Results	80
4. Discussion	86
5. Publications	87
II. Characteristics of human immunodeficiency virus type 1 (HIV-1) gp120 env sequences in mother-child pairs infected with HIV-1 subtype CRF01_AE	89

1. Background and specific aims	89
2. Materials and methods	90
3. Results	92
4. Discussion	102
5. Publications	104
III. Inpatient Recombination between Human Immunodeficiency Virus Type 1 Envelope Genes in Mother-to-Child Transmission	115
1. Background and specific aims	115
2. Materials and methods	115
3. Results	118
4. Discussion	128
5. Publications	129
CHAPTER 3 : CONCLUSION AND PERSPECTIVES	130
1. CONCLUSION	130
2. PERSPECTIVES	132
CHAPTER 4 : RÉSUMÉ (SUMMARY IN FRENCH)	134
CHAPTER 5 : REFERENCES	138
APPENDIX	176
APPENDIX A	176
APPENDIX B	179
CURRICULUM VITAE	185

LIST OF TABLES

Table		Page
1	Potential mechanisms by which neutralizing and non-neutralizing Abs modulate the HIV life cycle	51
2	Baseline characteristics of transmitting and non-transmitting mothers	76
3	Comparison of detectable neutralizing antibodies against the 6 primary isolates in transmitting and non-transmitting mothers	81
4	Neutralizing antibody titers of 10 serum samples against LEA, MBA and V2MBA-EnvΔV2LEA pseudotyped viruses. Results are expressed as the reciprocal dilution that reduces the RLU by 50%	84
5	Samples used during the present study	116
6	Nucleic acid codes	176
7	Amino acid codes	177
8	Standard genetic code	178
9	Different approaches to the use of ARV prophylaxis to prevent HIV infection in infants	180
10	ARV prophylaxis regimens for PMTCT among pregnant women living with HIV who have not received antepartum therapy or prophylaxis	183
11	ARV prophylaxis regimens for infants born to women living with HIV who have not received antepartum or intrapartum therapy or prophylaxis	185

LIST OF FIGURES

Figure		Page
1	Estimated number of people living with HIV globally during 1990-2007	4
2	Estimated number of adults and children to be living with HIV in 2007	5
3	Schematic representation of a mature HIV-1 virion (left) and a mature HIV-1 particle observed by electron cryotomography	7
4	Organization and landmarks of the HIV-1 DNA genome	8
5	Replication cycle of HIV-1	11
6	Schematic representation of the early steps of HIV-1 cell entry	12
7	Process of reverse transcription of HIV genome	14
8	Liner representation of the structure of HIV-1 envelope	17
9	Diagram of the structure of HIV-1 gp120 envelope glycoprotein	18
10	Comparison of the conformation and molecular surface of deglycosylated liganded HIV-1 HXB2 gp120 core with glycosylated unliganded SIV gp120 core	19
11	The HIV-1 gp120 structure	20-21
12	Diagram of the structure of HIV-1 gp41 envelope glycoprotein	24
13	V3 amino acid sequences and numbering according to HIV-1 HXB2	27

Figure	Page
14 Model for HIV-1 coreceptor usage and tropism <i>in vivo</i>	28
15 Phylogenetic relationship of HIV-1 group M, N, O, and CRFs	31
16 The mosaic pattern of the CRFs available in HIV sequence database	33
17 Global distribution and prevalence of HIV-1 subtypes and recombinant forms	34
18 Type of HIV dual infection and plasma viral load at different clinical stages	38
19 The HIV recombination process	39-40
20 Forced copy-choice model	42
21 Strand displacement-assimilation model	43
22 The distribution of breakpoints across HIV-1 genome	44
23 Time cause of HIV infection	49
24 Steps at which antibodies can potentially interfere with HIV-1 replication	52
25 The epitopes for the broadly neutralizing mAbs on HIV-1 envelope glycoprotein	54
26 Comparison of the direct epitope variation and the glycan shield models of HIV-1 immune escape	56
27 Percentage of women living with HIV from 1990 to 2007	58
28 Schematic representation of placenta structure	60-61
29 Mechanisms of <i>in utero</i> transmission	63
30 Origin of HIV in breast milk	65
31 Comparison of neutralizing antibody titers in transmitting (T) versus non-transmitting (NT) mothers	75

Figure	Page
32 Construction of the V2 chimeric Envs	79
33 Comparison of neutralizing antibody titers in transmitting (T) and non-transmitting (NT) mothers	82
34 Locations of the sequence characteristics of the envelope glycoprotein of MBA	83
35 Effect of the V2 domain of MBA on the neutralization of LEA	85
36 Unrooted neighbor-joining tree of the 353 HIV-1 <i>env</i> gp120 nucleotide sequences from 17 mother-child pairs	93
37 Unrooted neighbor-joining trees of HIV-1 <i>env</i> gp120 nucleotide sequences for each mother-child pair	94-96
38 Characteristics of the viral variants in mothers and infants in all pairs (n=17), in cases of in utero transmission only (n=6), and in cases of intrapartum transmission only (n=11).	98
39 Map of PNGS for each quasispecies present in either mother or infant	100- 101
40 Unrooted neighbor-joining trees of the 109 HIV-1 <i>env</i> gp120 nucleotide sequences from the two mother-child pairs	120- 123
41 Schematic representation of the recombination analysis for pairs 1005 and 0779	126
42 Alignment of HIV-1 <i>env</i> gp120 (V1-V5) amino acid consensus sequences of each group for pairs 1005 and 0779	127

ABBREVIATIONS

Ab	Antibody
ADCC	Antibody-directed cell-mediated cytotoxicity
AIDS	Acquired immune deficiency syndrome
APOBEC-3G	Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
ART	Antiretroviral therapy
ARV	AIDS-associated retrovirus
ARV	Antiretroviral
C	Constant
CCR5	CC-chemokine receptor 5
CD	Cluster of differentiation
CD4BS	CD4-binding site
CD4i	CD4-induced epitope
CDC	Centers for Disease Control and Prevention
CLR	Conditional logistic regression
cpx	Complex
CRFs	Circulating recombinant forms
CTL	Cytotoxic T lymphocyte
CXCR4	CXC-chemokine receptor 4
DCs	Dendritic cells
DC-SIGN	Dendritic cell specific ICAM-3 grabbing non-integrin
DNA	Deoxyribonucleic acid
D-tropic	Dual-tropic
Env	Envelope
ER	Endoplasmic reticulum
gp	Glycoprotein
HIV	Human immunodeficiency virus
HTLV	Human T-lymphotropic virus
HuMAbs	Human neutralizing monoclonal antibodies
IDU	Intravenous drug users
Ig	Immunoglobulin
IQR	Inter-quartile range
kDa	kilo Dalton
LAV	Lymphadenopathy-associated virus

LTNPs	Long-term non-progressors
LTR	Long terminal repeat
M	Major
mAb	Monoclonal antibody
mm ³	Cubic millimeter
MPER	Membrane proximal external region
mRNA	messenger Ribonucleic acid
MSM	Men who have sex with men
MTCT	Mother-to-child transmission
M-tropic	Macrophage-tropic
N	New, or non-M, non-O
NAb	Neutralizing antibody
NIH	National Institutes of Health
NNRTIs	Non-nucleoside reverse transcriptase inhibitors
NRTIs	Nucleoside reverse transcriptase inhibitors
NSI	Non-syncytium-inducing
NVP	Nevirapine
O	Outlier
PBMCs	Peripheral blood mononuclear cells
PCP	<i>Pneumocystis carinii</i> pneumonia
PCR	Polymerase chain reaction
PHPT	Perinatal HIV Prevention Trial
PI	Protease inhibitors
PMCHT	Prevention of mother-child HIV transmission
PNGS	Potential N-linked glycosylation sites
PSSM	Position-specific scoring matrix
RF	Random forest
RLU	Relative luminescence unit
RNA	Ribonucleic acid
RNase H	Ribonuclease H
RT	Reverse transcriptase
RT-PCR	Reverse transcriptase–polymerase chain reaction
SHIV	Simian-human immunodeficiency virus
SI	Syncytium-inducing
SIV	Simian immunodeficiency virus
SVM	Support vector machines
TCID ₅₀	50% tissue culture infectious dose
TCLA	T-cell line-adapted
tRNA	transfer RNA
T-tropic	T-cell line-tropic

URFs	Unique recombinant forms
V	Variable
VL	Viral load
ZDV	Zidovudine



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved